Press Releases

2020


January 9, 2020

Nkarta Therapeutics to Present at the J.P. Morgan Healthcare Conference


 

2019


December 9, 2019
Nkarta Therapeutics Expands Senior Management Team with Key Hires in Finance and Clinical Development


November 18, 2019
Nkarta Therapeutics Presents Preclinical Data for CD19 CAR NK Program


September 23, 2019
FierceBiotech: Nkarta Therapeutics recognized as 2019 Fierce 15 company.


September 18, 2019
Nkarta Therapeutics Promotes Nadir Mahmood, Ph.D., to Chief Business Officer


September 9, 2019
Nkarta Therapeutics Appoints Vice President of Regulatory Affairs


September 4, 2019
Nkarta Therapeutics Raises $114 Million in Series B Financing to Advance Multiple Programs into Clinical Trial


April 1, 2019
Nkarta Therapeutics Presents Data at Aacr Demonstrating Proprietary NK Cell Engineering and Expansion Technology Enhances Potency and Cytotoxicity Of NK Cells


 

2018


December 10, 2018
Nkarta Therapeutics announces appointment of Matthew Plunkett, Ph.D., as Chief Financial Officer


November 27, 2018
Nkarta Therapeutics Appoints Kanya Rajangam, M.D., Ph.D, as Chief Medical Officer


November 9, 2018
Nkarta Therapeutics Reports Potent Natural Killer Cell Anti-Cancer Activity In Preclinical Tumor Model


July 9, 2018
Nkarta Therapeutics Expands Management Team and Establishes New Corporate Headquarters


June 11, 2018
Nkarta Therapeutics Announces Exclusive License to Natural Killer Cell Technology from National University of Singapore and St. Jude Children’s Research Hospital


March 1, 2018
Nkarta Therapeutics Appoints Veteran Executive Paul Hastings As CEO To Lead Next Phase Of Growth